vorozole has been researched along with Experimental Mammary Neoplasms in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (64.29) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bartz, U; Bayer, H; Grün, G; Hartmann, RW; Mitrenga, M; Sergejew, T | 1 |
| Bode, A; Grubbs, CJ; Juliana, MM; Lubet, RA; Moeinpour, F; Steele, VE | 1 |
| Bode, AM; Christov, K; Ericson, ME; Grubbs, CJ; Juliana, MM; Lubet, RA; Steele, VE; Szabo, E | 1 |
| De Coster, R; Snoeck, E; Wouters, W | 1 |
| Casebolt, TL; Eto, I; Grubbs, CJ; Kelloff, GJ; Lubet, RA; Steele, VE | 1 |
| Callens, M; De Coster, R; Goeminne, N; Janssens, B; Van Ginckel, R; Wouters, L | 1 |
| Durgam, VR; Tekmal, RR | 1 |
| Bowden, C; DeCoster, R; Eto, I; Grubbs, CJ; Juliana, MM; Kelloff, GJ; Lubet, RA; Steele, VE; You, M | 1 |
| Iino, Y; Koibuchi, Y; Morishita, Y; Sugamata, N | 1 |
| Christov, K; Green, A; Grubbs, C; Kelloff, G; Lubet, R; Mehta, RG; Shilkaitis, A | 1 |
| Crist, KA; Grubbs, CJ; Hu, L; Johanning, GL; Lubet, RA; Wang, M; Wang, Y; Yao, R; You, M | 1 |
| Knott, KK; Lubet, RA; McGinley, JN; Steele, VE; Thompson, HJ | 1 |
| Callens, MJ; De Coster, R; Goeminne, NK; Janssens, BL; Van Ginckel, RF | 1 |
| Byloos, M; De Coster, R; Goeminne, N; Van Ginckel, R; Vanherck, W; Wouters, W | 1 |
1 review(s) available for vorozole and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
Vorozole, a specific non-steroidal aromatase inhibitor.
Topics: Animals; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Female; Hormones; Humans; In Vitro Techniques; Male; Mammary Neoplasms, Experimental; Triazoles | 1994 |
13 other study(ies) available for vorozole and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
Pyridyl-substituted tetrahydrocyclopropa[a]naphthalenes: highly active and selective inhibitors of P450 arom.
Topics: Adrenal Glands; Animals; Antineoplastic Agents; Aromatase Inhibitors; Cattle; Female; Humans; Liver; Male; Mammary Neoplasms, Experimental; Naphthalenes; Ovary; Placenta; Pyridines; Rats; Testis | 1995 |
Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKt inhibitor MK2206 in mammary cancer models.
Topics: Animals; Disease Models, Animal; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Heterocyclic Compounds, 3-Ring; Lapatinib; Male; Mammary Neoplasms, Experimental; Mice; Mice, Knockout; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; Triazoles | 2018 |
Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bexarotene; Biomarkers, Tumor; Carcinogens; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Therapy, Combination; ErbB Receptors; Female; Gefitinib; Immunoenzyme Techniques; Mammary Neoplasms, Experimental; Methylnitrosourea; Phosphorylation; Quinazolines; Rats; Rats, Sprague-Dawley; Tetrahydronaphthalenes; Triazoles | 2008 |
Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats.
Topics: Adenocarcinoma; Aminoglutethimide; Androstenedione; Animals; Anticarcinogenic Agents; Aromatase Inhibitors; Drug Screening Assays, Antitumor; Estrus; Female; Mammary Neoplasms, Experimental; Methylnitrosourea; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Triazoles | 1994 |
Effects of combined and sequential treatment with tamoxifen and the aromatase inhibitor vorozole on 7,12-dimethylbenz(a) anthracene-induced mammary carcinoma in the rat.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Administration, Oral; Androstenedione; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Carcinogens; Disease Models, Animal; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Luteinizing Hormone; Mammary Neoplasms, Experimental; Ovariectomy; Progesterone; Rats; Rats, Sprague-Dawley; Tamoxifen; Triazoles | 1996 |
A novel in vitro and in vivo breast cancer model for testing inhibitors of estrogen biosynthesis and its action using mammary tumor cells with an activated int-5/aromatase gene.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Aminoglutethimide; Analysis of Variance; Anastrozole; Androstenedione; Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Division; Enzyme Inhibitors; Fadrozole; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Ovariectomy; Postmenopause; Triazoles; Tumor Cells, Cultured | 1997 |
Chemopreventive effects of the aromatase inhibitor vorozole (R 83842) in the methylnitrosourea-induced mammary cancer model.
Topics: Animals; Antineoplastic Agents; Aromatase Inhibitors; Body Weight; Carcinogens; Drug Administration Schedule; Drug Screening Assays, Antitumor; Estradiol; Estrus; Female; Genes, ras; Insulin-Like Growth Factor I; Mammary Neoplasms, Experimental; Methylnitrosourea; Rats; Rats, Sprague-Dawley; Testosterone; Triazoles | 1998 |
A novel aromatase inhibitor, vorozole, shows antitumor activity and a decrease of tissue insulin-like growth factor-I level in 7, 12-dimethylbenz[a]anthracene-induced rat mammary tumors.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Administration, Oral; Animals; Antineoplastic Agents; Aromatase Inhibitors; Enzyme Inhibitors; Female; Insulin-Like Growth Factor I; Mammary Neoplasms, Experimental; Rats; Triazoles | 1999 |
Cellular responses of mammary carcinomas to aromatase inhibitors: effects of vorozole.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aromatase Inhibitors; Biomarkers, Tumor; Cell Division; Dose-Response Relationship, Drug; Enzyme Inhibitors; Estradiol; Female; Mammary Neoplasms, Experimental; Rats; Rats, Sprague-Dawley; Triazoles | 2000 |
Altered gene expression profile in chemically induced rat mammary adenocarcinomas and its modulation by an aromatase inhibitor.
Topics: Adenocarcinoma; Amino Acid Sequence; Animals; Aromatase; Aromatase Inhibitors; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Inhibitors; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization; Mammary Neoplasms, Experimental; Methylnitrosourea; Molecular Sequence Data; Oligonucleotide Array Sequence Analysis; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Sequence Homology, Amino Acid; Triazoles; Up-Regulation | 2001 |
Effect of the aromatase inhibitor vorozole on estrogen and progesterone receptor content of rat mammary carcinomas induced by 1-methyl-1-nitrosourea.
Topics: Animals; Antineoplastic Agents; Aromatase Inhibitors; Cell Division; Diet; Drug Administration Schedule; Epithelial Cells; Female; Immunoenzyme Techniques; Mammary Neoplasms, Experimental; Methylnitrosourea; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2001 |
Antitumoral and endocrine effects of (+)-vorozole in rats bearing dimethylbenzanthracene-induced mammary tumors.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Aromatase Inhibitors; Drug Administration Schedule; Drug Screening Assays, Antitumor; Estradiol; Female; Follicle Stimulating Hormone; Luteinizing Hormone; Mammary Neoplasms, Experimental; Ovariectomy; Random Allocation; Rats; Rats, Inbred Strains; Triazoles | 1992 |
Endocrine and antitumoral effects of R76713 in rats.
Topics: Adrenal Cortex Hormones; Adrenal Glands; Animals; Antineoplastic Agents; Aromatase Inhibitors; Body Weight; Estradiol; Female; Luteinizing Hormone; Mammary Neoplasms, Experimental; Organ Size; Ovariectomy; Ovary; Progesterone; Rats; Rats, Inbred Strains; Triazoles; Uterus | 1990 |